Get started
Author

Tonya L. Villafana

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 4,615
PDF
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
2021 · Shabir A. Madhi, Vicky Baillie, et al. · New England Journal of Medicine · 1,259
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
2021 · Shuo Feng, Daniel J. Phillips, et al. · Nature Medicine · 1,163
PDF
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
2021 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 1,119
PDF
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
2020 · M. Pamela Griffin, Yuan Yuan, et al. · New England Journal of Medicine · 768
PDF
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
2021 · Katherine R W Emary, Tanya Golubchik, et al. · The Lancet · 603
PDF
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
2008 · Philip Bejon, John Lusingu, et al. · New England Journal of Medicine · 417
PDF
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
2023 · Eric A F Simões, Shabir A Madhi, et al. · The Lancet Child & Adolescent Health · 320
PDF
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
2023 · William J. Muller, Shabir A. Madhi, et al. · New England Journal of Medicine · 245
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
2008 · Salim Abdulla, Rolf Oberholzer, et al. · New England Journal of Medicine · 239
PDF
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
2018 · Joseph B. Domachowske, Anis A. Khan, et al. · The Pediatric Infectious Disease Journal · 230
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
2022 · Joseph Domachowske, Shabir A. Madhi, et al. · New England Journal of Medicine · 192
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial
2011 · Ally Olotu, John Lusingu, et al. · The Lancet Infectious Diseases · 170
Recruitment and Retention of Pregnant Women Into Clinical Research Trials: An Overview of Challenges, Facilitators, and Best Practices
2014 · P. M. Frew, D. S. Saint-Victor, et al. · Clinical Infectious Diseases · 155
PDF
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
2016 · M. Pamela Griffin, Anis A. Khan, et al. · Antimicrobial Agents and Chemotherapy · 148
PDF
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
2021 · Shabir A Madhi, Anthonet L Koen, et al. · The Lancet HIV · 145
PDF
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
2022 · Meera Madhavan, Adam J. Ritchie, et al. · EBioMedicine · 144
PDF
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
2023 · Deidre Wilkins, Yuan Yuan, et al. · Nature Medicine · 132
PDF
An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
2017 · Judith Falloon, Jing Yu, et al. · The Journal of Infectious Diseases · 131
PDF
Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine
2011 · Christine Swysen, Johan Vekemans, et al. · Malaria Journal · 100
PDF
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
2011 · Ally Olotu, Philippe Moris, et al. · PLoS ONE · 96
PDF
Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012
2017 · Susan T. Pastula, Judith Hackett, et al. · Open Forum Infectious Diseases · 93
PDF
A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
2009 · Bertrand Lell, Selidji Agnandji, et al. · PLoS ONE · 88
PDF
Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine
2012 · Amir Horowitz, Julius C R Hafalla, et al. · The Journal of Immunology · 84
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
2023 · Bahar Ahani, Kevin M. Tuffy, et al. · Nature Communications · 81
PDF
Works count: 95
Citation count: 13,870
H-index: 37
I10-index: 54
Year
Topic
Type